Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes
A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

NCT07415954

RecruitingPhase 2

Sponsor: Novo Nordisk A/S

Conditions: Diabetes Mellitus, Type 2

Interventions: NNC0662-0419, Semaglutide, Placebo

Countries: United States, Croatia, Hungary, Japan, Poland, Portugal, Slovakia, South Korea

This study is being done to look at the effect and safety of different doses of NNC0662-0419 in people living with type 2 diabetes when compared to placebo or semaglutide. The purpose of this clinical study is to find out if NNC0662-0419 is effective and safe for treating people living with type 2 diabetes. Participants will get either NNC0662-0419, semaglutide or placebo. Which treatment participants get is decided by chance. NNC0662-0419 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Semaglutide is an approved medication to treat type 2 diabetes.

Eligibility overview

Sex: ALL

Age: 18 Years to 75 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion criteria

* Male or female (sex at birth).
* Age 18-75 years (both inclusive) at the time of signing the informed consent.
* Glycated haemoglobin (HbA1c) of 7.0-10.0 percent (%) (53-86 millimoles per mole \[mmol/mol\]) (both inclusive) as assessed by central laboratory at screening.
* Willingness to obtain a high weight loss (greater than \[\>\] 25% of weight at baseline).

Exclusion criteria

* Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.
* Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
* Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's Questionnaire.
Locations (63)
  • Lancaster, California, United States
  • Lomita, California, United States
  • Long Beach, California, United States
  • Los Alamitos, California, United States
  • San Diego, California, United States
  • Walnut Creek, California, United States
  • Hollywood, Florida, United States
  • Miami, Florida, United States
  • Miramar, Florida, United States
  • Ocoee, Florida, United States
  • Weston, Florida, United States
  • Blackfoot, Idaho, United States
  • Chicago, Illinois, United States
  • Boston, Massachusetts, United States
  • Springfield, Missouri, United States
  • Greensboro, North Carolina, United States
  • Statesville, North Carolina, United States
  • Dayton, Ohio, United States
  • Memphis, Tennessee, United States
  • Dallas, Texas, United States
  • Houston, Texas, United States
  • Shavano Park, Texas, United States
  • Kingwood, West Virginia, United States
  • Karlovac, Croatia
  • Osijek, Croatia
  • Varaždin, Croatia
  • Zagreb, Croatia
  • Szeged, Csongrád-Csanád, Hungary
  • Debrecen, Hajdú-Bihar, Hungary
  • Debrecen, Hungary
  • + 33 more on CT.gov